A new clinical trial is investigating the efficacy of CBD-infused mouthwashes and toothpaste when used to treat gum disease.
The randomised controlled clinical trial is a collaboration between Australian medicinal cannabis business Impression Healthcare and US-based pharmaceutical-grade medical cannabis producer AXIM Biotechnologies.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.